Please assess the completion status of the following clinical trial:

Trial Title: Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-resectable, histologically confirmed, epithelial growth factor receptor(EGFR)-positive or negative colorectal cancer~* WHO Performance status 0 or 1~* Signed written informed consent~* ≥ 18 years of age~* Effective contraception for both male and female subjects if the risk of conception exists~* Adequate bone marrow function: neutrophil blood cell count (NBC) ≥ 1.5 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, hemoglobin ≥ 5.96 mmol/L (10 g/dL)~* Adequate liver and renal function: bilirubin ≤ 1.5 x upper normal level (UNL) and not increasing more than 25% within the last 4 weeks; ASAT and ALAT ≤ 5 x UNL; serum creatinine ≤ 1.5 x UNL.~Exclusion Criteria:~* Previous exposure to epidermal growth factor receptor-targeting therapy~* Previous chemotherapy for colorectal cancer except for adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment or 5-FU in combination with radiotherapy for rectal cancer~* Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before inclusion.~* Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy.~* Investigational agents or participation in clinical trials within 30 days before start of the treatment in study.~* Clinically relevant coronary disease or myocardial infarction within 12 months before study entry.~* Peripheral neuropathy \> CTC (Common Toxicity Criteria)grade I~* Inflammatory bowel disease~* Previous malignancy (except for colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)~* History of severe psychiatric illness~* Drug or alcohol abuse~* Known hypersensitivity reaction to any of the components of study treatment~* Pregnancy (absence to be confirmed by b-hCG (pregnancy-) test) or lactation period~* Brain metastasis and/or leptomeningeal disease (known or suspected)~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab+ FOLFOXIRI (Type: EXPERIMENTAL): Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).